We serve Chemical Name:N-(5-Bromo-3-nitropyridin-2-yl)acetamide CAS:381679-24-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-(5-Bromo-3-nitropyridin-2-yl)acetamide
CAS.NO:381679-24-9
Synonyms:2-acetamido-5-bromo-3-nitropyridine
Molecular Formula:C7H6BrN3O3
Molecular Weight:260.04500
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:423.5ºC at 760mmHg
Density:1.808g/cm3
Index of Refraction:1.656
PSA:87.81000
Exact Mass:258.95900
LogP:2.30690
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-acetamido-5-bromo-3-nitropyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-acetamido-5-bromo-3-nitropyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-acetamido-5-bromo-3-nitropyridine Use and application,2-acetamido-5-bromo-3-nitropyridine technical grade,usp/ep/jp grade.
Related News: At present, API companies basically use multi-functional and multi-purpose workshops, and the main equipment uses multi-functional reactors to achieve flexible utilization of production capacity. N-(5-Bromo-3-nitropyridin-2-yl)acetamide manufacturer After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API. N-(5-Bromo-3-nitropyridin-2-yl)acetamide supplier China is now dealing with another disease outbreak �� this one mostly affecting animals but also potentially deadly among people. N-(5-Bromo-3-nitropyridin-2-yl)acetamide vendor After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API. N-(5-Bromo-3-nitropyridin-2-yl)acetamide factory When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau.
